12/120
0.5 / 5 stars
All 120 Win/Lose results shown below
BOLT Roast Me summary
Bolt Biotherapeutics, Inc. (BOLT). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseBOLT / S&P -4.70% / 15.20% |
LoseBOLT / S&P 12.79% / 15.00% |
LoseBOLT / S&P BOLT unavailable / 50.40% |
| 2026-Q11/3 |
LoseBOLT / S&P -26.12% / -4.33% |
WinBOLT / S&P 78.64% / 11.30% |
LoseBOLT / S&P BOLT unavailable / 27.70% |
| 2025-Q41/3 |
WinBOLT / S&P 2.78% / 2.65% |
LoseBOLT / S&P 0.07% / 9.00% |
LoseBOLT / S&P BOLT unavailable / 13.40% |
| 2025-Q30/3 |
LoseBOLT / S&P -7.80% / 8.12% |
LoseBOLT / S&P -46.88% / 4.61% |
LoseBOLT / S&P BOLT unavailable / 13.45% |
| 2025-Q20/3 |
LoseBOLT / S&P -27.88% / 10.94% |
LoseBOLT / S&P -62.68% / 4.83% |
LoseBOLT / S&P BOLT unavailable / 10.63% |
| 2025-Q10/3 |
LoseBOLT / S&P -25.23% / -4.27% |
LoseBOLT / S&P -67.87% / 4.98% |
LoseBOLT / S&P BOLT unavailable / 10.57% |
| 2024-Q40/3 |
LoseBOLT / S&P -17.44% / 2.41% |
LoseBOLT / S&P -2.36% / 5.25% |
LoseBOLT / S&P BOLT unavailable / 6.15% |
| 2024-Q31/3 |
LoseBOLT / S&P -13.60% / 5.89% |
WinBOLT / S&P 35.86% / 5.89% |
LoseBOLT / S&P BOLT unavailable / 6.11% |
| 2024-Q21/3 |
LoseBOLT / S&P -46.43% / 4.28% |
WinBOLT / S&P 64.64% / 5.38% |
LoseBOLT / S&P BOLT unavailable / 5.12% |
| 2024-Q12/3 |
WinBOLT / S&P 25.00% / 10.56% |
WinBOLT / S&P 67.96% / 5.71% |
LoseBOLT / S&P BOLT unavailable / 5.59% |
| 2023-Q41/3 |
LoseBOLT / S&P 7.69% / 11.69% |
WinBOLT / S&P 37.48% / 6.81% |
LoseBOLT / S&P BOLT unavailable / 7.78% |
| 2023-Q31/3 |
LoseBOLT / S&P -18.75% / -3.27% |
WinBOLT / S&P 49.15% / 7.52% |
LoseBOLT / S&P BOLT unavailable / -5.03% |
| 2023-Q21/3 |
LoseBOLT / S&P -7.91% / 8.74% |
WinBOLT / S&P 95.67% / 9.50% |
LoseBOLT / S&P BOLT unavailable / -8.57% |
| 2023-Q11/3 |
LoseBOLT / S&P 6.92% / 7.50% |
WinBOLT / S&P 225.23% / 10.77% |
LoseBOLT / S&P BOLT unavailable / -15.69% |
| 2022-Q41/3 |
LoseBOLT / S&P -12.16% / 7.56% |
WinBOLT / S&P 354.68% / 11.88% |
LoseBOLT / S&P BOLT unavailable / -17.99% |
| 2022-Q30/3 |
LoseBOLT / S&P -27.45% / -4.88% |
LoseBOLT / S&P BOLT unavailable / 13.47% |
LoseBOLT / S&P BOLT unavailable / -1.41% |
| 2022-Q20/3 |
LoseBOLT / S&P -25.55% / -16.10% |
LoseBOLT / S&P BOLT unavailable / 13.71% |
LoseBOLT / S&P BOLT unavailable / 11.04% |
| 2022-Q10/3 |
LoseBOLT / S&P -44.08% / -4.60% |
LoseBOLT / S&P BOLT unavailable / 15.97% |
LoseBOLT / S&P BOLT unavailable / 42.23% |
| 2021-Q41/3 |
LoseBOLT / S&P -61.26% / 11.03% |
WinBOLT / S&P 445.45% / 15.00% |
LoseBOLT / S&P BOLT unavailable / 96.40% |
| 2021-Q30/3 |
LoseBOLT / S&P -18.18% / 0.58% |
LoseBOLT / S&P BOLT unavailable / 10.77% |
LoseBOLT / S&P BOLT unavailable / 69.42% |
| 2021-Q20/3 |
LoseBOLT / S&P -53.02% / 8.55% |
LoseBOLT / S&P BOLT unavailable / 6.58% |
LoseBOLT / S&P BOLT unavailable / 51.81% |
| 2021-Q10/3 |
LoseBOLT / S&P BOLT unavailable / 6.17% |
LoseBOLT / S&P BOLT unavailable / -1.06% |
LoseBOLT / S&P BOLT unavailable / 7.39% |
| 2020-Q40/3 |
LoseBOLT / S&P BOLT unavailable / 12.15% |
LoseBOLT / S&P BOLT unavailable / -3.72% |
LoseBOLT / S&P BOLT unavailable / -33.42% |
| 2020-Q30/3 |
LoseBOLT / S&P BOLT unavailable / 8.93% |
LoseBOLT / S&P BOLT unavailable / -2.04% |
LoseBOLT / S&P BOLT unavailable / -27.10% |
| 2020-Q20/3 |
LoseBOLT / S&P BOLT unavailable / 20.54% |
LoseBOLT / S&P BOLT unavailable / -0.46% |
LoseBOLT / S&P BOLT unavailable / -27.11% |
| 2020-Q10/3 |
LoseBOLT / S&P BOLT unavailable / -19.60% |
LoseBOLT / S&P BOLT unavailable / 3.47% |
LoseBOLT / S&P BOLT unavailable / -14.75% |
| 2019-Q40/3 |
LoseBOLT / S&P BOLT unavailable / 9.07% |
LoseBOLT / S&P BOLT unavailable / 5.36% |
LoseBOLT / S&P BOLT unavailable / 2.99% |
| 2019-Q30/3 |
LoseBOLT / S&P BOLT unavailable / 1.70% |
LoseBOLT / S&P BOLT unavailable / 5.02% |
LoseBOLT / S&P BOLT unavailable / 0.21% |
| 2019-Q20/3 |
LoseBOLT / S&P BOLT unavailable / 4.30% |
LoseBOLT / S&P BOLT unavailable / 6.64% |
LoseBOLT / S&P BOLT unavailable / 8.65% |
| 2019-Q10/3 |
LoseBOLT / S&P BOLT unavailable / 13.65% |
LoseBOLT / S&P BOLT unavailable / 8.12% |
LoseBOLT / S&P BOLT unavailable / 14.29% |
| 2018-Q40/3 |
LoseBOLT / S&P BOLT unavailable / -13.52% |
LoseBOLT / S&P BOLT unavailable / 9.05% |
LoseBOLT / S&P BOLT unavailable / 18.23% |
| 2018-Q30/3 |
LoseBOLT / S&P BOLT unavailable / 7.71% |
LoseBOLT / S&P BOLT unavailable / 10.21% |
LoseBOLT / S&P BOLT unavailable / 19.06% |
| 2018-Q20/3 |
LoseBOLT / S&P BOLT unavailable / 3.43% |
LoseBOLT / S&P BOLT unavailable / 9.03% |
LoseBOLT / S&P BOLT unavailable / 14.46% |
| 2018-Q10/3 |
LoseBOLT / S&P BOLT unavailable / -0.76% |
LoseBOLT / S&P BOLT unavailable / 7.68% |
LoseBOLT / S&P BOLT unavailable / 12.46% |
| 2017-Q40/3 |
LoseBOLT / S&P BOLT unavailable / 6.64% |
LoseBOLT / S&P BOLT unavailable / 7.03% |
LoseBOLT / S&P BOLT unavailable / 13.82% |
| 2017-Q30/3 |
LoseBOLT / S&P BOLT unavailable / 4.48% |
LoseBOLT / S&P BOLT unavailable / 5.68% |
LoseBOLT / S&P BOLT unavailable / 17.57% |
| 2017-Q20/3 |
LoseBOLT / S&P BOLT unavailable / 3.09% |
LoseBOLT / S&P BOLT unavailable / 4.83% |
LoseBOLT / S&P BOLT unavailable / 17.74% |
| 2017-Q10/3 |
LoseBOLT / S&P BOLT unavailable / 6.07% |
LoseBOLT / S&P BOLT unavailable / 3.67% |
LoseBOLT / S&P BOLT unavailable / 13.32% |
| 2016-Q40/3 |
LoseBOLT / S&P BOLT unavailable / 3.82% |
LoseBOLT / S&P BOLT unavailable / 2.09% |
LoseBOLT / S&P BOLT unavailable / 7.05% |
| 2016-Q30/3 |
LoseBOLT / S&P BOLT unavailable / 3.85% |
LoseBOLT / S&P BOLT unavailable / 0.20% |
LoseBOLT / S&P BOLT unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | BOLT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -23.73% | 20.78% |
| Annualized return | -23.73% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | BOLT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -98.87% | 83.14% |
| Annualized return | -59.23% | 12.86% |
10Y · 2021-02-05 to 2026-08-28
| Metric | BOLT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.39% | 319.30% |
| Annualized return | -39.96% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |